Aprogen
↗Seongnam-si, South Korea
Aprogen Inc. is a prominent South Korean biopharmaceutical company focused on the development and large-scale manufacturing of biosimilars and novel biologics. Founded in 2000 by researchers from KAIST and KRIBB, it gained significant recognition as the first Korean biotechnology company to achieve 'Unicorn' status (valuation over $1 billion). The company operates through several entities, including Aprogen Biologics and Aprogen Medicines, following a series of strategic mergers to consolidate its R&D and manufacturing capabilities.
The company is best known for its proprietary antibody engineering technologies, such as SDR-grafting and CHIMPS bispecific antibody platforms. Aprogen maintains one of the largest cGMP-compliant manufacturing facilities in South Korea, located in Osong, which supports both its internal pipeline and CDMO services. Its lead product, an infliximab biosimilar (GS071), is successfully marketed in Japan and South Korea through partnerships with Nichi-Iko Pharmaceuticals.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Biosimilars and Novel Biologics
SIZE & FINANCIALS
Employees:501-1000
Revenue:$89M-$110M
Founded:2000
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$167M
Investors:Nichi-Iko Pharmaceutical, Lindeman Asia Investment, G-Base
STOCK
Exchange:KRX
Ticker:003060 (Biologics) / 007460 (Medicines)
Market Cap:$106M
PIPELINE
Stage:Commercial
Lead Drug Stage:Marketed (GS071)
Modalities:mAb, Bispecific antibody, Biosimilar, Recombinant protein
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:G-Base (Holding Company)
Subsidiaries:Aprogen Biologics Inc., Aprogen Medicines Inc., AP Healthcare Inc.
Key Partnerships:Nichi-Iko Pharmaceutical (Global licensing and distribution for GS071), Schnell Life Sciences (Domestic distribution in Korea)
COMPETITION
Position:Challenger
Competitors:Celltrion, Samsung Bioepis, Samsung Biologics, Sandoz, Amgen
LEADERSHIP
Key Executives:
Seungho Rhee - CEO
Kim Jae-seop - Founder & Chairman
Scientific Founders:Kim Jae-seop
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Aprogen and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Aprogen. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.